Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Agreement further expands Aptar Pharma’s leading respiratory portfolio
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The companies will leverage their respective proprietary technology platforms
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
New facility is part of Aptar Pharma’s global expansion program
Subscribe To Our Newsletter & Stay Updated
